everolimus (EVE) via the CellTiter-Glo assay. Two EVE-sensitive cell lines (786-O and A-498) were constantly exposed to EVE and resistant cell lines (786-O EST and A-498 EST, respectively) were established. A comparative analysis was then performed between the established and primary cell lines.
INTRODUCTION AND OBJECTIVES: Clear cell renal cell carcinoma (ccRCC) is clinically silent at their earliest stages, therefore, at the time of the initial diagnosis, up to 30% of patients have already progressed to a locally advanced disease state or exhibit metastases. cAMP responsive element binding protein 1 (CREB1) is a proto-oncogene in various cancer. This study was to explore the function and clinical significance of phosphorylated cAMP responsive element binding protein 1 (p-CREB1) at Ser 133 site in advanced ccRCC. The CREB1 phosphorylate pathway may be a novel target for kidney therapy.
METHODS: The expression of p-CREB1 (Ser133) and non p-CREB1 (Ser133) is determined by immunohistochemistry (IHC) in 151 advanved ccRCC patients. Through constructing lentiviral vector and using small molecular inhibitor, 666-15, the phosphorylated CREB (Ser133) are knockdown, overexpressed and inhibited. The proliferation of 786-0 cells in vitro and in vivo was determined by clone formation assay, MTS assay, and subcutaneous tumor formation in nude mice. To investigate the mechanisms, the interacting proteins of CREB1 were precipitated by pull-down assay and identified by mass spectrum. Then the proteins interaction was confirmed by co-immunoprecipitation in kidney cancer cells. Protein and mRNA expression level were measured by western blot and qPCR, respectively.
RESULTS: P-CREB1 (Ser133) and non p-CREB1 (Ser133) is highly expressed in ccRCC tissues. In multi-factor regression analysis, p-CREB1 (Ser133) is an independent risk factor but not non p-CREB1. The clone formation and proliferation ability is inbibted by phosphorylated CREB1 (Ser133) knockdown and 666-15, however, reversed by CREB1 (Ser133) overexpression. And subcutaneous tumor in nude mice is significantly shrinked by treating with 666-15.The interaction of CREB1 with serine/threonine-protein kinase 1 (SRPK1) and casein kinase II subunit beta (CSNK2B) were identified and confirmed in kidney cancer cells. The expression of p-CREB1 (Ser133) protein was higher in SRPK1 and CSNK2B overexpressed cells.Knockdown SRPK1 and CSNK2B, the p-CREB1 (Ser133) protein was decreased, the proliferation and migration ability were attenuated, and the cell apoptosis was induced in kidney cancer cells.
CONCLUSIONS: Highly expressed p-CREB (Ser133) is an independent risk of ccRCC patient. CREB1 was activated by SRPK1 and CSNK2 through phosphorylation. Target CREB1 phosphorylate pathway may inhibit the cancer phenotype of ccRCC. METHODS: RCC and its paired normal kidney tissues were immunohistochemically stained for RASAL2 expression. Databases downloaded from TCGA or GEO were used to analyze the methylation status of RASAL2 and the correlation between RASAL2 and c-FOS or VEGFA in RCC tissues. In vitro, RASAL2 gain-function in 786-O cells or loss-function in ACHN cells were measured for the recruitment and tube formation of human umbilical vein endothelial cell (HUVEC) by HUVEC migration assay and tube formation assay, ELISA assay and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tunorigenicity. Moreover, the expression of RASAL2, VEGFA and CD31 in RCC tissues and xenografts were detect by immunohistochemical (IHC) staining.
RESULTS: The expression of RASAL2 was downregulated in RCC tissues, and RASAL2 mRNA was inversely correlated with Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1203
